Synapse
⌘+K
Sign In
Sign Up for Free
Synapse
Sign In
Sign Up for Free
Home
Communities
Explore
More
Language
English
English
Roche (China)
h-index: 63
Total citations: 25,352
Total papers: 638
Homepage:
http://www.roche.com/
Recent papers from Roche (China)
Rapid target engagement of KRAS G12C tricomplex inhibitor RO3903 overcomes resistance and drives durable tumor regression
Proceedings of the National Academy of Sciences · 2026
Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial
The Lancet · 2023
Bibliometric mapping reveals global inequities and therapeutic evolution in triple-negative breast cancer brain metastasis research
Discover Oncology · 2026
Multimodal characterization of HLA-G expression across solid tumors reveals transcript-protein discordance and implications for immunotherapy targeting
Frontiers in Immunology · 2026
Atezolizumab plus pertuzumab, trastuzumab, and chemotherapy in HER2-positive early breast cancer: final results of the phase III IMpassion050 trial
ESMO Open · 2026
Aptamer recognition driven cascaded biocomputation on surface of serum-derived small extracellular vesicles
Journal of Nanobiotechnology · 2026
A machine learning-based prediction model for 30-day mortality in patients with infective endocarditis
BMC Medical Informatics and Decision Making · 2026
Atezolizumab plus chemotherapy for Asian vs. non-Asian patients with extensive-stage small-cell lung cancer: A propensity score matched pooled analysis of four phase 3 trials
Lung Cancer · 2026
Development and validation of machine learning models for 30-day mortality prediction in septic shock
Frontiers in Microbiology · 2026
Glofitamab in combination with immunochemotherapy in patients with relapsed/refractory B‐cell non‐Hodgkin lymphoma: Phase 1b dose‐escalation study
British Journal of Haematology · 2026
Final analysis of the FeDeriCa phase III study: long-term efficacy, safety and pharmacokinetics of the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection, plus chemotherapy, in HER2-positive early breast cancer
ESMO Open · 2026
Adjuvant alectinib versus platinum-based chemotherapy in patients from Asia with completely resected ALK-positive non-small cell lung cancer (NSCLC): an exploratory subgroup analysis of ALINA including pharmacokinetics and safety in Japanese patients
International Journal of Lung Cancer · 2026
A New Role of Class A Hepatitis B Virus Capsid Assembly Modulators in Core Protein Dynamics and Covalently Closed Circular DNA Replenishment
Cellular and Molecular Gastroenterology and Hepatology · 2026
Atezolizumab with or without tiragolumab in unresectable esophageal squamous cell carcinoma following definitive concurrent chemoradiotherapy (SKYSCRAPER-07): a randomised, phase III study
Annals of Oncology · 2026
Structure-Based Design of Potent TLR7/8/9 Triple Antagonists: Overcoming High Tissue Distribution and Reactive Metabolite Liabilities
Journal of Medicinal Chemistry · 2026
A phase Ib/II, open-label, multicenter, randomized umbrella study evaluating the combination of atezolizumab with sacituzumab govitecan in patients with locally advanced or metastatic urothelial carcinoma and previously treated with a platinum-based treatment regimen (MORPHEUS-Urothelial Carcinoma)
ESMO Open · 2026
An interpretable XGboost algorithm for predicting 30-day mortality in acute pancreatitis using routine biomarkers
BMC Medical Research Methodology · 2026
CSD-Net: Content–Style Decoupling with Exploratory MLLM-Guided Refinement for Robust Change Detection
Remote Sensing · 2026
A TNFR2 biparatopic antagonist reverses immune suppression through a crosslinking-resistant and ADCC- independent mechanism
Journal of Leukocyte Biology · 2026
Preclinical evaluation of the newly developed carina platform in robotic-assisted proctectomy with porcine and cadaveric models
Scientific Reports · 2026